Holen Sie sich die Stockscreener-App
9.63
2.53%
-0.25
Schlusskurs vom Vortag:
$9.88
Offen:
$10.1
24-Stunden-Volumen:
354.79K
Relative Volume:
1.38
Marktkapitalisierung:
$282.94M
Einnahmen:
$1.78M
Nettoeinkommen (Verlust:
$-151.77M
KGV:
-1.6609
EPS:
-5.7981
Netto-Cashflow:
$-79.40M
1W Leistung:
+19.48%
1M Leistung:
+39.77%
6M Leistung:
+30.84%
1J Leistung:
-3.70%
1-Tages-Spanne:
$9.45
$10.39
1-Wochen-Bereich:
$7.90
$10.59
52-Wochen-Spanne:
$5.60
$15.57
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Firmenname
Cartesian Therapeutics Inc
Sektor
Branche
Telefon
301-348-8698
Adresse
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
9.63 | 282.94M | 1.78M | -151.77M | -79.40M | -5.7981 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-09 | Eingeleitet | Wedbush | Outperform |
| 2024-12-19 | Eingeleitet | BTIG Research | Buy |
| 2024-08-06 | Eingeleitet | TD Cowen | Buy |
| 2024-07-02 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2024-05-24 | Eingeleitet | Mizuho | Buy |
| 2024-04-23 | Bestätigt | H.C. Wainwright | Buy |
| 2024-04-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-18 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Bestätigt | Needham | Buy |
| 2022-06-06 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-01-26 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-10-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-10-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Herabstufung | Stifel | Buy → Hold |
| 2020-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-01-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Eingeleitet | William Blair | Outperform |
| 2018-06-27 | Eingeleitet | Janney | Buy |
| 2017-03-30 | Bestätigt | UBS | Buy |
Alle ansehen
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
Cartesian Therapeutics Shareholders Back Directors and Governance Measures - TipRanks
Shareholders of Cartesian Therapeutics (NASDAQ: RNAC) back board, pay and auditor - Stock Titan
Cartesian Therapeutics Inc (RNAC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cartesian Therapeutics Inc (RNAC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cartesian Therapeutics Inc (RNAC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cartesian Therapeutics Inc (RNAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cartesian Therapeutics Inc PE Ratio (TTM) & PE Ratio (TTM) ChartsRNAC - GuruFocus
Cartesian Therapeutics (RNAC) Slides 7.2% as Support Nears $8.38Corrective Wave - newsline.com
New partnership gives Cartesian Therapeutics another shot at autoimmune disease market - MSN
RNAC Q1 2026 Earnings: Disappointing EPS Miss Yet Stock Surges 18%Earnings Weakness Phase - newsline.com
Cartesian Therapeutics Announces New Employment Inducement Grant - The Manila Times
New hire at Cartesian gets 6,100 stock options vesting to 2030 - Stock Titan
Cartesian climbs on licensing deal with WestGene for CAR-T therapies - MSN
RNAC: Directors elected and all proposals passed with strong support; no stockholder questions submitted - TradingView
Cartesian Therapeutics, Inc. (RNAC) soars 10.3%: Is further upside left in the stock? - MSN
Cartesian Eyes Multiple 2026-2027 Readouts As Descartes-08 Advances Toward Potential BLA - RTTNews
RNAC Reiterated by Wedbush -- Price Target Maintained at $38.00 - GuruFocus
RNAC Reiterated by BTIG -- Price Target Maintained at $44.00 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cartesian Therapeutics (RNAC) and Abbott Laboratories (ABT) - The Globe and Mail
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Announces Target Price $40 - Moomoo
Morgan Stanley Smith Barney (RNAC) lists exercises, vesting and a 3,924-share resale - Stock Titan
RNAC Reiterated by Needham -- Price Target Maintained at $40 - GuruFocus
Cartesian Therapeutics (RNAC) Shares Surge 30% on Licensing Agre - GuruFocus
WestGene Biopharma to collaborate with Cartesian Therapeutics on in vivo CAR-T for autoimmune disease - Traders Union
Cartesian partners with WestGene for in vivo autoimmune CAR-T - grafa.com
Cartesian inks licensing deal with WestGene (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics stock jumps on WestGene partnership deal - Investing.com UK
Cartesian Therapeutics stock jumps on WestGene partnership deal By Investing.com - Investing.com Australia
Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance - TipRanks
Cartesian strikes licensing agreement with WestGene - The Pharma Letter
Cartesian Therapeutics | 8-K: Current report - Moomoo
Cartesian Therapeutics (RNAC) licenses in vivo CAR-T delivery tech from WestGene - Stock Titan
Cartesian Therapeutics Announces Strategic Licensing Agreement With Westgene Biopharma To Accelerate The Development Of In Vivo Car-T Platform In Autoimmune Diseases - TradingView
Experimental in vivo CAR-T for myasthenia gravis could skip lab manufacturing - Stock Titan
Cartesian Therapeutics (RNAC) Slides 10.8% as Stock Tests Key Support LevelsVol Target Rebalance - newsline.com
Cartesian Therapeutics (RNAC) Faces Sharp Decline, Testing Key Support LevelsADD Alert - newsline.com
[144] Cartesian Therapeutics, Inc. SEC Filing - Stock Titan
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Cartesian Therapeutics (RNAC) Rises 3.33% as Stock Holds Above Key SupportHedge Fund Exposure - The Legal Advocate
Cartesian Therapeutics (RNAC) Gains 4.6% as Biotech Sector Shows Renewed InterestInstitutional Sentiment - The Legal Advocate
H.C. Wainwright Keeps Their Buy Rating on Cartesian Therapeutics (RNAC) - The Globe and Mail
Cartesian Therapeutics secures up to $150 million financing - The Pharma Letter
Cartesian Therapeutics (RNAC) Secures $150M Credit Facility for Growth Initiatives - GuruFocus
RNAC Maintained by Needham -- Price Target Lowered to $40.00 - GuruFocus
Cartesian Therapeutics stock price target maintained at $40 by Mizuho - Investing.com
Cartesian Therapeutics secures $150M non-dilutive financing, advancing CAR-T trials with key data expected in 2027. - Pluang
Cartesian Therapeutics Secures $150 Million Loan Agreement with K2 HealthVentures and Ankura Trust Company - Minichart
Cartesian Therapeutics Secures Up to $150 Million Credit Facility From K2 HealthVentures - marketscreener.com
Cartesian Therapeutics Lands Up to $150 Million in Non-Dilutive Financing to Support CAR-T Commercialization Push - citybiz
Finanzdaten der Cartesian Therapeutics Inc-Aktie (RNAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):